Terms of Use
The logos of various companies displayed on Fey.com are for editorial and informational purposes only. Fey.com is not affiliated with, sponsored by, or endorsed by these companies. All logos are trademarks of their respective owners and are used under the principles of fair use. We make no claim of ownership over these trademarks.
Restrictions on Use
While we provide these logos for individual download and personal use, any form of automated scraping or bulk downloading of logos from Fey.com is strictly prohibited. Users are permitted to download logos manually, one at a time, as intended through our user interface. Unauthorized mass retrieval or use of logos will be considered a violation of our terms and may result in restricted access or legal action. For concerns or inquiries regarding the use of any logo, please contact us at info@fey.com.
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-α-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.